New to PETMETRIX PULSE? This 'start-here' guide covers the PULSE schema, how to separate 'Observed' facts from 'Assessed' interpretation, and a 15‑minute routine to turn each edition into owner‑assigned actions, segmented by operator group.
Three state policy moves and one membership launch hit the same control point this week: who reaches the pet owner first and where the case goes next. Georgia, Washington, and Connecticut each moved a remote-care or staffing bill, while Thrive added after-hours advice, booking, and live call-note sharing to Thrive Plus.
State policy drove this week’s biggest pet Rx signals. New telehealth, VCPR, dispensing, and licensure moves in four states, plus FDA’s first generic injectable robenacoxib approval, reshaped clinic control over follow-up, hiring speed, and formulary economics.
FDA approval of NUMELVI, a new JAK inhibitor for canine allergic dermatitis, and Zoetis’ genomics acquisition highlight shifting control points in the veterinary prescription market. PETMETRIX PULSE examines protocol control, clinic launch sequencing, and emerging upstream competition.
The pet Rx market battlefield is moving upstream. Chewy is entering clinics and vet workflow to capture default refills, while the Covetrus–MWI merger concentrates distribution leverage and risk. With FTC scrutiny hardening and premium therapeutics accelerating, operators should prioritize refill-without-friction, consolidation readiness, and payment/claims automation.
